dr. mascarenhas on the potential role of pacritinib in mpns
Published 3 years ago • 210 plays • Length 1:37Download video MP4
Download video MP3
Similar videos
-
1:38
dr. mascarenhas on the need to develop curative therapies in myelofibrosis
-
2:00
dr. mascarenhas on approved and emerging treatment options in myelofibrosis
-
2:16
dr. mascarenhas discusses pacritinib in myelofibrosis
-
1:28
dr. mascarenhas on the mpd-rc 112 study in pv and essential thrombocythemia
-
4:59
john mascarenhas, md, ms: continuing to evaluate pacritinib for myelofibrosis
-
11:03
a phakic solution to the presbyopia problem: the trailblazing artiflex presbyopic from ophtec
-
26:53
isth academy presentation: acquired thrombotic thrombocytopenic purpura
-
5:54
treating intermediate/high-risk primary myelofibrosis
-
3:52
dr mascarenhas discusses mds/mpn overlap for patients
-
40:09
new drugs for mpns - dr. john mascarenhas
-
15:35
what are mpns? top specialist talks symptoms and diagnosis | dr. john mascarenhas
-
2:45
what to expect when starting mpn inhibitor therapy
-
3:21
emerging agents pacritinib and momelotinib for mf
-
2:47
mpn research and optimism about curative therapies
-
5:10
pacritinib activity against myelofibrosis
-
0:42
dr. rampal on ongoing research with pacritinib in myelofibrosis
-
1:52
dr. john mascarenhas on the comfort-i/ii studies for ruxolitinib in myelofibrosis
-
2:59
how do mpns progress from one disease to the next?
-
2:17
pacritinib for the treatment of patients with myelofibrosis
-
6:08
ruxolitinib’s role in treating myelofibrosis
-
2:22
what are the benefits of mpn inhibitor treatment?
-
1:17
the use of pacritinib in thrombocytopenic patients with myelofibrosis undergoing allosct